CliffBio
small molecule

DEXAMETHASONE

DEXAMETHASONE SODIUM PHOSPHATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEXAMETHASONE
Active ingredientDEXAMETHASONE SODIUM PHOSPHATE
StrengthEQ 10MG PHOSPHATE/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJanuary 1984
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.